Vision

Vision has been quietly reclassified along the same arc as hearing. The eye is no longer treated as an isolated sensory organ; it is a systemic biomarker of microvascular aging, a mitochondrial demand-test of the highest-energy tissue in the body, and a measurable input to cognitive trajectory. The 2024 Lancet Commission added untreated visual impairment to the modifiable dementia list, though with a population attributable fraction of only about 2% — smaller than hearing loss or high cholesterol.^[1] The past few years have also produced an oculomics literature in which deep-learning models read fundus photographs to predict cardiovascular events, biological age, and all-cause mortality — a genuine research advance, though not yet standard clinical care.

Why vision is on the longevity short list

Three independent signals converge:

1. Dementia (modest, unresolved). Untreated visual impairment is among the modifiable risk factors in the 2024 Lancet Commission framework, but it is one of the smaller levers — a population attributable fraction of roughly 2%, well below hearing loss or high LDL cholesterol, and causality remains unresolved (shared neuropathology, sensory deprivation, and reverse causation are all plausible).^[2] Cross-sectional analyses of the NIH All of Us program (about 287,000 participants) show people with any form of age-related macular degeneration (AMD) have higher odds of concurrent dementia in fully adjusted models.^[3] The relationship is largely mediated by functional vision loss rather than shared pathology — blindness substantially increases Alzheimer's risk while non-exudative AMD without severe impairment does not.^[4] The practical implication is identical to hearing: treat the deficit early. (Evidence: moderate for the association; causality unresolved.)
2. All-cause mortality. Deep-learning analysis of routine fundus photographs now generates a "Retinal Age Gap" (RAG) — the difference between predicted retinal age and chronological age — that is one of the most robust non-invasive mortality predictors yet validated. UK Biobank cohort analysis (n = 35,913) found each one-year increase in the gap is associated with a 2% rise in all-cause mortality (hazard ratio, HR, 1.02), with steeper increases in non-cardiovascular and non-cancer mortality at the upper quartiles.^[5]
3. Cardiovascular surveillance. The retinal microvasculature is the only vascular bed visible non-invasively. Quantitative changes in vessel caliber, density, and tortuosity precede clinical cardiovascular events and now feed AI models that estimate coronary artery calcium scores directly from a fundus image.^[6]

A retinal exam is therefore an unusually information-dense image — though the systemic-aging read-outs below remain research tools, not part of a standard eye-exam report.

Oculomics: the retina as a biological-age clock

(Weak–preliminary — research-stage, not clinical care.) The models below are genuine and rapidly improving, but none is validated or endorsed for routine screening of healthy adults. Read this section as a preview of where the field is heading, not as advice to seek out any particular scan.

Two takeaways:

• The retina is a promising aging clock. In the studies published so far, fundus-derived RAG has predicted mortality about as well as some DNA-methylation clocks, from a 30-second clinic photo rather than a blood draw — a striking result, though direct head-to-head validation is limited and no professional body yet uses it for risk stratification.^[12]
• The signals are not interchangeable across sex. RETFound's analysis suggests male retinal aging tracks metabolic stress, while female retinal aging tracks vascular remodeling — a useful nuance for interpreting the same image differently in primary prevention.^[13]

The clinical infrastructure is still uneven, and most adults will not receive a Retinal Age Gap on a regular eye-exam printout. OCT is now routine in many practices and worth having when it is offered as part of a comprehensive exam, but there is no professional-society basis for asking for OCT-angiography or an AI aging-clock read-out as a healthy-adult screening test. The high-yield ask is simply a thorough dilated exam on the cadence below.

The macula: lutein, zeaxanthin, and MPOD

The macula's structural and functional integrity depends on the bioaccumulation of two dietary xanthophyll carotenoids — lutein and zeaxanthin — that uniquely cross the blood-retina barrier and concentrate in the fovea. Their concentration is measured clinically as macular pigment optical density (MPOD).

These pigments do two physical jobs:

1. Filter short-wavelength blue-violet light before it can damage photoreceptors. At a high MPOD (~1.60), the macular pigment absorbs roughly 97.5% of incident short-wave visible light.^[14]
2. Quench reactive oxygen species in the retina, the most metabolically demanding tissue in the body and consequently the most exposed to oxidative damage.^[15]

The visual-performance consequences of higher MPOD are real and measurable in healthy adults: faster visual processing, better contrast sensitivity, faster dark adaptation (up to roughly two minutes faster after bright-light exposure), and improved glare recovery.^[16] Low MPOD is a pre-disease biomarker for AMD: in one comparative analysis, fellow eyes of AMD patients overwhelmingly met criteria for critically low MPOD or shortened photoreceptor outer segments before clinical disease appeared.^[17]

A newer and more speculative idea is that lutein might act systemically before it concentrates in the eye. A 2025 cross-sectional analysis using the Klemera-Doubal Method (a multi-organ biological-age algorithm) found higher combined lutein + zeaxanthin intake associated with slightly attenuated biological aging (odds ratio 0.93 — a 7% lower likelihood of accelerated aging) and lower all-cause mortality.^[18] The mechanistic story is consistent: in laboratory work, lutein scavenges hepatic lipid peroxides, reduces pro-inflammatory Th1 cells, suppresses the senescence-associated secretory phenotype, and supports telomere stability.^[19] Treat this as observational and hypothesis-generating, not established: people who eat more lutein also eat more vegetables and tend toward healthier lifestyles overall, so much of the apparent benefit is likely healthy-user confounding rather than a direct effect of the carotenoid. (Evidence: weak-preliminary.)

How to actually get enough

The AREDS2 trial tested 10 mg lutein + 2 mg zeaxanthin, but it is easy to over-read the result. Adding lutein/zeaxanthin to the core antioxidant-plus-zinc formula produced no significant additional benefit in the primary analysis; the value of lutein/zeaxanthin is that it works at least as well as beta-carotene as the carotenoid in the formula while avoiding beta-carotene's lung-cancer risk in smokers, with a modest edge in secondary analyses (about 15% lower 10-year progression to late AMD versus beta-carotene, hazard ratio 0.85).^[20] The broader picture from the 2023 Cochrane review (26 trials, nearly 12,000 people): lutein or zeaxanthin alone "may have little or no effect" on AMD progression, whereas the full antioxidant-plus-zinc formula "probably slows progression to late AMD" (odds ratio 0.72 — about 28% lower odds of progression) — so lutein is best understood as one component of a formula, not a standalone eye supplement. (Evidence: moderate — Cochrane, moderate certainty for the full formula.)^[21] Most adults consume far less than the roughly 6–10 mg/day of lutein associated with neuroprotective MPOD levels.

The food-first route is straightforward:

• Cooked spinach — by far the densest practical source (~20 mg lutein per cup cooked).
• Cooked kale, collards, Swiss chard — similar order of magnitude.
• Egg yolks — the lutein matrix is highly bioavailable due to the lipid carrier.
• Orange/yellow peppers, corn — primary zeaxanthin sources.

A reasonable midlife default: leafy greens daily, eggs regularly. Targeted AREDS2-formulation supplementation is appropriate for people with diagnosed intermediate AMD; for healthy adults, the food-first pattern is what the systemic-aging data actually rests on.

Cognition: the decisive trial was null

Lutein concentrations in the macula track lutein concentrations in the brain, which makes MPOD a usable surrogate for central-nervous-system carotenoid status — a plausible reason to expect a cognitive benefit. The largest and most relevant test of that hypothesis found none. The AREDS2 cognition sub-trial randomised more than 3,000 older adults (mean age 73) to lutein/zeaxanthin, omega-3 fatty acids, both, or placebo and followed cognitive function double-masked: lutein/zeaxanthin had no statistically significant effect on cognition, and omega-3 was likewise null. (Evidence: strong — large RCT in the relevant age group.)^[22]

The often-cited positive result comes from a much smaller study: a double-masked, placebo-controlled trial of just 51 healthy adults aged 18–30, in which a year of lutein + zeaxanthin supplementation raised MPOD and improved spatial memory, reasoning, and complex attention.^[23] That is a small, preliminary trial in a young population, and for an aging readership the large null trial in older adults should take precedence. The honest read: the food-first route incurs no downside, but do not expect a cognitive payoff from a lutein pill.

The vision-loss → dementia pathway

The mechanism connecting vision loss to cognitive decline mirrors the hearing story, with one important nuance:

• Sensory deprivation reduces neuroplasticity, social engagement, mobility, and environmental complexity — the same psychosocial pathway that makes hearing loss the largest single modifiable midlife dementia factor. See Hearing and Purpose.
• Visual impairment specifically drives social withdrawal in the late midlife window because reading, driving, facial recognition, and screen use all collapse together.
• Shared pathology (amyloid-beta, oxidative stress, microvascular dysfunction) is real but appears to contribute less than functional impairment. All of Us data and a 2026 analysis suggest the dementia signal scales with visual severity rather than AMD diagnosis per se.^[24]

The implication: uncorrected vision is the modifiable variable. Cataract surgery, glasses, low-vision rehabilitation, and AMD treatment that preserves function are not cosmetic interventions — they preserve the sensory bandwidth that maintains cognitive engagement. The same logic that has converted hearing aids from "vanity" to "evidence-based dementia prevention" applies to vision correction and AMD management.

The psychological burden of progressive vision loss compounds the biology: AMD patients exhibit elevated rates of clinical depression and anxiety, and chronic stress further accelerates the systemic biological aging that drives the underlying disease.^[25] Vision rehabilitation and psychological support belong in the AMD treatment plan, not after it.

The conditions you're most likely to actually get

The frontier material above is genuinely interesting, but the eye problems an aging reader will most likely develop and act on are older, better-studied, and more treatable. This is where the strongest evidence lives.

Cataract

Cataract is the leading cause of blindness worldwide — responsible for roughly 45% of global blindness, around 17 million people blind and tens of millions more with moderate-to-severe vision impairment.^[26] The main modifiable risk factors are smoking, diabetes, systemic and inhaled corticosteroids, alcohol, and ultraviolet light — though the UV link is subtype-specific, consistent for cortical (and some posterior subcapsular) cataract but inconsistent for the nuclear type. Certified UV-blocking sunglasses are a cheap, high-value hedge.

Cataract surgery is one of the highest-value operations in medicine, and its benefits reach beyond acuity. In a randomised trial, first-eye surgery in women over 70 cut the overall falling rate by about a third (rate ratio 0.66). (Evidence: strong — RCT.)^[27] A nuance worth knowing: the companion trial of second-eye surgery did not significantly reduce falls, so the largest fall-prevention gain comes from operating on the first eye.^[28] Observational data also link cataract extraction to roughly 29% lower dementia risk over the following decade, with glaucoma surgery (which does not restore vision) showing no such association — an internal comparison that supports a vision-specific pathway, though the finding remains observational and open to healthy-patient selection bias. (Evidence: moderate — large cohort with a plausible control.)^[29]

Glaucoma

Glaucoma is asymptomatic until it is advanced, and intraocular pressure is the only major modifiable risk factor. Higher-risk groups include older adults, people with a family history, those of Black or Hispanic/Latino ancestry, high myopes, and people with diabetes. The practical message is simply to be examined on schedule, because early disease is silent and the vision it takes does not come back.

Treatment has a clear evidence-based front line. The LiGHT trial randomised more than 700 people with newly diagnosed glaucoma or ocular hypertension to selective laser trabeculoplasty (a quick outpatient laser) versus daily eye drops; at six years, about 70% of laser-first eyes still needed no drops, with less disease progression and fewer patients needing surgery.^[30] That establishes laser as a reasonable first-line option, not just a fallback. (Evidence: strong — RCT.) One calibration on screening: the US Preventive Services Task Force concluded in 2022 that evidence is insufficient to recommend population glaucoma screening in asymptomatic adults, so the case-finding here happens within a comprehensive eye exam rather than as a standalone screening program.^[31] Exercise acutely lowers intraocular pressure and is broadly good for the eye, but evidence that it prevents glaucoma is weak, and heavy resistance training with breath-holding can transiently spike pressure.

Dry eye disease

Dry eye becomes common with age and is more frequent in women: US survey data put diagnosed prevalence at about 7% of adults overall, rising from under 3% in young adults to nearly 19% in those 75 and older.^[32] A widely believed remedy does not hold up: the large, double-masked DREAM trial gave symptomatic patients 3,000 mg/day of fish oil and found it no better than placebo on dry-eye signs or symptoms, a null result confirmed in the trial's extension. (Evidence: strong for the null — large RCT.)^[33] Prolonged screen work worsens evaporative symptoms mainly because people blink far less while staring at a display — which is exactly what the 20-20-20 rule (every 20 minutes, look 20 feet / 6 metres away for 20 seconds) is meant to counter.

Myopia and refractive error

For children, the strongest lever against myopia is outdoor time. A cluster-randomised trial added 40 minutes of outdoor school time per day and cut 3-year myopia onset from about 40% to 30% — roughly a quarter fewer new cases. (Evidence: strong — RCT.)^[34] The effect is on onset, not on slowing progression once a child is already myopic. The adult relevance is that high myopia raises lifetime risk of retinal detachment, myopic maculopathy, and glaucoma — a reason for high myopes to keep to a more frequent exam schedule.

Diabetic retinopathy

Blood-sugar control is the dominant modifiable lever here: intensive glycemic control sharply reduces both the onset and the progression of retinopathy in diabetes. This is really a metabolic problem expressed in the eye — see Metabolic flexibility and Glycemic index for the systemic picture.

Mitochondria, supplements, and saffron

The retina has the highest oxygen consumption rate of any tissue in the body and the densest concentration of mitochondria. Most age-related visual decline in structurally intact eyes is a mitochondrial energy problem — declining ATP synthesis in the retinal pigment epithelium and photoreceptor layer, with rising reactive oxygen species and the cascade that culminates in drusen, RPE apoptosis, and AMD.^[35]

The supplement landscape splits into three tiers:

Tier 1 — established AMD-modifying:

• AREDS-type formulation (10 mg lutein, 2 mg zeaxanthin, vitamins C and E, zinc, copper) for people with intermediate AMD or advanced AMD in one eye. The original AREDS trial cut 5-year progression to advanced AMD by about a quarter — but only in people who already had intermediate AMD or advanced disease in one eye; there was no benefit in early AMD or in healthy eyes, which is the single most important thing to know before buying it. (Evidence: strong — large RCT.) AREDS2 then swapped beta-carotene for lutein/zeaxanthin after beta-carotene was linked to lung cancer in smokers.^[36] This is a treatment for diagnosed intermediate disease, not a healthy-adult preventive.

Tier 2 — preliminary, surrogate-endpoint only:

• Saffron (Crocus sativus L.) — 20–30 mg/day. The evidence here is thin and easy to over-sell. There is no Cochrane review and no meta-analysis of saffron for AMD, because the trials are too few, too small, and too heterogeneous to pool. The largest randomised trial (about 100 participants, 3-month crossover) found a clinically trivial gain of well under one line of visual acuity, and the 12-month open-label extension found visual acuity actually drifted slightly worse even as an electroretinogram surrogate marker improved.^[37] Most saffron trials are small, several are open-label, and the literature clusters within a few author groups and saffron-producing regions — grounds for caution about publication and conflict-of-interest bias. A separate randomised pilot in primary open-angle glaucoma reported a modest intraocular-pressure reduction.^[38] Bottom line: interesting mechanism, but the outcome data are preliminary, surrogate-endpoint, and not a reason to add saffron to established care. (Evidence: weak-preliminary.)

Tier 3 — systemic mitochondrial support, essentially no retinal-outcome data:

CoQ10, NAD+ precursors (NMN, NR), and resveratrol all have plausible mitochondrial mechanisms and are sometimes marketed for eye health, but none has meaningful clinical-outcome data in the retina. They are general mitochondrial/longevity supplements, not eye supplements, and are better evaluated against the core supplement evidence on their own merits.

For healthy midlife adults, the honest read: AREDS-type formulas belong to people with diagnosed intermediate AMD; saffron is preliminary and surrogate-endpoint at best; and the mitochondrial stack has no retinal outcome data. None of these is a reason to skip the interventions with real evidence — cataract and glaucoma care, correcting refractive error, not smoking, and a good diet.

Photobiomodulation: the 670 nm finding

One of the more surprising recent findings in ophthalmic gerontology is that brief morning exposure to deep-red light (670 nm) may measurably improve age-related visual decline — though the supporting trials are tiny and the endpoints are surrogates, so treat this as an intriguing early signal rather than a proven intervention.

The mechanism is biophysical: long-wavelength deep-red light penetrates tissue and stimulates cytochrome c oxidase in the mitochondrial electron transport chain, while reducing the viscosity of the nano-scale water layer around ATP synthase pumps — increasing their mechanical efficiency and rescuing ATP output in energy-starved cells.^[39]

In a UCL Institute of Ophthalmology trial of subjects aged 38–70, a single three-minute exposure to 670 nm light improved cone-mediated color contrast thresholds, with the functional gains persisting roughly a week.^{[40] [41]}

The timing matters more than the dose. The improvements were seen only when exposure was administered in the morning; the same protocol delivered in the afternoon produced no effect — consistent with mitochondrial circadian gating.^[42]

Not every study agrees. A controlled trial that followed people with intermediate AMD and healthy older eyes for 12 months found no benefit on the structural endpoints that matter — no change in drusen volume and no improvement in outer nuclear (photoreceptor) layer thickness — and no functional gain in the AMD group.^[43]

The honest read: the positive data are a handful of small, short pilots using a color-contrast surrogate endpoint, and a longer controlled study was null on structure. It is not standard of care; consumer 670 nm devices vary widely in irradiance and spectral purity; and long-term clinical outcomes are unknown. Plausible and low-risk, but the confidence should be low. (Evidence: weak-preliminary.)

Blue light: deconstructed

The opposite end of the visible spectrum has been the subject of a decade of consumer-product marketing that the clinical evidence does not support.

A current systematic review and meta-analysis of randomized crossover trials of blue-light-blocking glasses (BBGs) found no statistically significant effect on objective sleep outcomes — the reduction in sleep onset latency was on the order of three minutes and not significant; the change in wake-after-sleep-onset was similarly trivial.^[44] BBGs also show minimal effect on contrast sensitivity, color discrimination, or digital eye strain.^[45]

The strongest single source is the 2023 Cochrane review of blue-light-filtering lenses (17 randomised trials): it found "little or no" effect on visual fatigue, best-corrected visual acuity, or sleep, and no randomised evidence at all on macular health. (Evidence: strong — Cochrane.)^[46] For context, screens emit on the order of a thousandth of the blue light of daylight, and typical blue-blocking glasses filter only a fraction of it. The American Academy of Ophthalmology's standing position is likewise that blue light from digital devices does not cause eye disease and special eyewear is not recommended for computer use; the 20-20-20 rule and sensible screen ergonomics are what's evidence-based.^[47]

Two practical caveats:

• Most BBGs fail to reach the optical filtering threshold needed to actually reduce melanopic input. An analysis of 26 commercial models found the majority do not hit the melanopic daylight filtering density (mDFD) threshold required for a meaningful physiological effect on circadian signaling.^[48]
• Daytime full-spectrum natural light exposure is what matters. The biologically necessary long-wavelength input for retinal mitochondria comes from outdoor light, and morning sun anchors the circadian clock through melanopsin-expressing retinal ganglion cells. See Sun exposure and Circadian rhythms.

The pragmatic takeaway: skip the BBGs, get outdoors in the morning, dim screens at night, and treat insomnia with sleep hygiene (or evaluation for sleep-disordered breathing) rather than with optical filters.

Lifestyle inputs to retinal aging

The same systemic interventions that move cardiovascular and dementia risk also move retinal-aging biomarkers — which is the point of treating the retina as a biosensor in the first place.

Circadian alignment

The retina has its own peripheral circadian clock, and the Clock and Cycle transcription factors govern roughly half of the active genes in photoreceptors.^[49] Photoreceptor proteins degrade on light exposure and must be re-synthesized on a daily schedule; circadian disruption mis-times that synthesis and accelerates photoreceptor decline.^[50] AMD patients exhibit delayed sleep-wake cycles and impaired morning function compared with healthy controls.^[51] See Circadian rhythms.

Aerobic exercise

A cross-sectional analysis of nearly 43,000 type 2 diabetes patients found higher physical activity associated with wider central retinal arteriolar equivalents and narrower venular equivalents — the favorable microvascular signature.^[52] Endurance training upregulates serum and retinal brain-derived neurotrophic factor (BDNF), reduces intraocular pressure modestly (~2–5 mmHg), and increases retinal blood flow. High-intensity interval training improves retinal flicker-light dilatation — a marker of endothelial reactivity — and reduces central macular thickness in adults with cardiovascular risk factors.^[53] See Zone 2 and VO₂ max.

Time-restricted eating

Murine AMD models induced by oxidative stress show that intermittent fasting prevents RPE and photoreceptor degeneration, suppresses microglial and Müller-cell hyperactivation, and reduces retinal ROS — even when the fasting protocol is initiated late in life.^[54] The human extrapolation is moderate at best, but the mechanism (AMPK / SIRT1 activation, mTOR suppression, mitochondrial biogenesis) is consistent with what TRE is doing systemically.^[55] A 2025 network meta-analysis of older adults supports moderate 16:8 protocols for cardiometabolic outcomes; very restrictive eating windows (<8 hours) and prolonged fasts trended toward worse cardiovascular outcomes in this population.^[56] See Fasting.

UV protection

Chronic UV exposure is an established risk factor for cataract and contributes to AMD. The intervention is unglamorous and cheap: real UV-blocking sunglasses on bright days. See Sun exposure.

A practical vision protocol for healthy midlife adults

1. Get a comprehensive dilated eye exam by age 40, then on a risk-adjusted cadence. For asymptomatic adults without risk factors, a reasonable schedule is roughly every 2–4 years in your 40s, every 1–3 years from 55, and every 1–2 years from 65 — sooner and more often with diabetes, a family history of glaucoma, Black or Hispanic/Latino ancestry, or high myopia. This is a full dilated exam that checks for cataract, glaucoma, diabetic retinopathy, and AMD — not a population "glaucoma screening," which the evidence does not yet support. OCT is worth having when it's offered as part of that exam; there is no need to seek out OCT-angiography or an AI "aging clock" as a healthy-adult test.
2. Treat any correctable visual loss promptly. Glasses, cataract surgery, AMD management — the dementia and mortality literature behaves the same way as the hearing literature. A condition you've been told about but not addressed is the modifiable factor.
3. Eat the macula. Leafy greens daily (cooked spinach is the densest practical source), eggs regularly, orange/yellow peppers and corn for zeaxanthin. Aim for the dietary pattern, not the supplement, unless you have intermediate AMD — in which case AREDS2 is established and your ophthalmologist will guide you.
4. Wear real UV-blocking sunglasses on bright days. Broad-spectrum coverage; the cheap pair from the gas station is fine if it's certified.
5. Skip the blue-light glasses. They don't move sleep or eye-strain endpoints in well-controlled trials. If you struggle with screens, treat that with the 20-20-20 rule, brightness/font adjustments, and a real ophthalmologic workup — not optical placebo.
6. Get morning sunlight. It anchors the circadian clock and provides full-spectrum input to the retina. See Circadian rhythms and Sun exposure.
7. Train both ways and don't smoke. Exercise improves retinal microvasculature on objective imaging; smoking is a large independent AMD risk factor. The ear and the eye respond to the same systemic levers as the heart and brain.
8. Don't count on saffron, red-light devices, or "eye supplements." The saffron and 670 nm data are small, short, and surrogate-endpoint; a longer controlled 670 nm study was null; and NMN/NR/resveratrol/CoQ10 have no retinal-outcome evidence. If you have diagnosed intermediate AMD, the established move is an AREDS-type formula under your ophthalmologist's guidance — not a frontier add-on.
9. Treat hearing loss in parallel. The two sensory pathways feed into the same dementia pathway. Addressing both compounds the protective effect. See Hearing.
10. Sleep close to 8 hours and aim for circadian regularity. Photoreceptor protein turnover is clock-gated; AMD patients show measurable circadian disruption. Sleep is not unrelated to the eye.

What's overhyped or wrong

• "Blue light from screens damages your eyes." It does not, in adults under normal exposure conditions. The American Academy of Ophthalmology is explicit about this; the multi-billion-dollar BBG market is consumer marketing ahead of clinical evidence.^[57]
• "Lutein supplements are all you need for eye health." Lutein is one input. Microvascular health (blood pressure, glycemic control, smoking status, exercise) drives more of the variance than carotenoid intake does. Take both seriously.
• "AMD is just an eye disease." It is the visible expression of a systemic mitochondrial-and-microvascular aging process. The retina is the diagnostic; the disease is closer to the rest of the body's aging biology than to a localized pathology.
• "Red light therapy reverses aging vision." The 670 nm mechanism is real, but the human evidence is a handful of tiny pilots on a color-contrast surrogate, and a 12-month controlled study found no structural benefit. It is plausible and low-risk, not proven.
• "Omega-3 supplements treat dry eye." The large DREAM trial found fish oil no better than placebo. Dry eye is better managed with lid hygiene, artificial tears, screen breaks, and evaluation for the underlying cause.
• "Lutein supplements alone slow AMD." Cochrane finds lutein or zeaxanthin alone has little or no effect; the benefit belongs to the full antioxidant-plus-zinc formula, and only in people who already have intermediate AMD.
• "Cataract surgery is purely cosmetic / can wait indefinitely." It cuts falls in a randomised trial and is associated with lower dementia risk. Untreated cataract in the late midlife window is a quietly expensive choice.
• "Eye exams just check whether you need glasses." A modern dilated exam with OCT screens for diabetic retinopathy, AMD, glaucoma, and increasingly the systemic biomarkers above. The signal density per visit is high.

Further reading

• Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet 2024.^[58]
• Zhu Z et al. Retinal age gap as a predictive biomarker for mortality risk. British Journal of Ophthalmology 2023.^[59]
• Grimbly MJ et al. Estimating biological age from retinal imaging: a scoping review. BMJ Open Ophthalmol 2024.^[60]
• RETFound — sex-divergent retinal aging signatures from foundation models. medRxiv 2025.^[61]
• The oculomics paradigm — comprehensive review. Optometry Times 2025.^[62]
• Stringham JM et al. Lutein across the Lifespan: From Childhood Cognitive Performance to the Aging Eye and Brain. Curr Dev Nutr 2019.^[63]
• Renzi-Hammond LM et al. Effects of a lutein and zeaxanthin intervention on cognitive function — RCT in healthy young adults. Nutrients 2017.^[64]
• Lutein and zeaxanthin intake and multi-organ biological aging. Frontiers in Nutrition 2025.^[65]
• Effects and mechanisms of lutein on aging. PMC 2024.^[66]
• Macular pigment optical density and photoreceptor outer segments as predisease AMD biomarkers. PMC 2020.^[67]
• Carotenoids in age-related macular degeneration — systematic review. Antioxidants 2021.^[68]
• Saffron therapy for ongoing AMD treatment — 12-month extension. PMC 2024.^[69]
• Saffron as a retinal neuroprotectant — narrative review. Antioxidants 2025.^[70]
• Gu X et al. Age-related macular degeneration and dementia: association through pathogenesis or visual impairment? J Alzheimers Dis 2026.^[71]
• NIH All of Us — AMD and dementia association. Review of Optometry 2025.^[72]
• Aging retinal function improved by 670 nm near-infrared light. PMC.^[73]
• Morning exposure to deep red light improves declining eyesight. UCL News 2021.^[74]
• Khorrami-Nejad M et al. Blue-light-filtering spectacle lenses in managing vision-related symptoms — an updated review. PMC 2026.^[75]
• Blue-blocking glasses & actigraphic sleep — meta-analysis of RCTs. PMC 2025.^[76]
• Optimizing utility of blue-blocking glasses for sleep and circadian health. TVST 2024.^[77]
• Circadian disruption & retinal physiopathology — expert consensus. PMC 2022.^[78]
• AMD and circadian preference. PMC 2025.^[79]
• Streese L et al. Physical activity and exercise improve retinal microvascular health. 2020.^[80]
• Intermittent fasting attenuates glial hyperactivation and photoreceptor degeneration in NaIO3 AMD model. PMC 2025.^[81]
• Intermittent fasting and healthy aging in older adults — systematic review and network meta-analysis. Nutrients 2025.^[82]
• Antioxidants in age-related macular degeneration — lights and shadows. PMC 2025.^[83]
• Chew EY et al. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 2015.^[84]
• Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2023.^[85]
• Chew EY et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements — AREDS2 Report 28. JAMA Ophthalmology 2022.^[86]
• Singh S et al. Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults. Cochrane Database of Systematic Reviews 2023.^[87]
• Global estimates on the number of people blind or visually impaired by cataract — meta-analysis 2000–2020. Eye 2024.^[88]
• Harwood RH, Foss AJE et al. Falls and health status in elderly women following first eye cataract surgery: a randomised controlled trial. British Journal of Ophthalmology 2005.^[89]
• Foss AJE et al. Falls and health status in elderly women following second eye cataract surgery: a randomised controlled trial. Age and Ageing 2006.^[90]
• Lee CS et al. Association between cataract extraction and development of dementia. JAMA Internal Medicine 2022.^[91]
• Gazzard G et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 2019.^[92]
• US Preventive Services Task Force. Screening for primary open-angle glaucoma: recommendation statement. JAMA 2022.^[93]
• Farrand KF et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. American Journal of Ophthalmology 2017.^[94]
• Asbell PA et al. n-3 fatty acid supplementation for the treatment of dry eye disease (DREAM). New England Journal of Medicine 2018.^[95]
• He M et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA 2015.^[96]
• Grewal MK et al. A pilot study evaluating the effects of 670 nm photobiomodulation in healthy ageing and age-related macular degeneration. Journal of Clinical Medicine 2020.^[97]

---